サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：急性群発発作の世界市場 - 世界の業界分析、規模、シェア、成長、動向、地域別見通し、予測（2023年～2030年）
市場調査レポート
商品コード
1371541

急性群発発作の世界市場 - 世界の業界分析、規模、シェア、成長、動向、地域別見通し、予測（2023年～2030年）

Acute Repetitive Seizures Market - Global Acute Repetitive Seizures Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2030 -

出版日
ページ情報
英文 240 Pages
納期
2～5営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
急性群発発作の世界市場 - 世界の業界分析、規模、シェア、成長、動向、地域別見通し、予測（2023年～2030年）
出版日: 2023年10月10日
発行: Fairfield Market Research
ページ情報: 英文 240 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の急性群発発作の市場規模は、2023年から2030年にかけて30％のCAGRで拡大し、2030年までに135億米ドルに達すると予測されています。

急性群発発作市場を推進する主要動向の1つは、発作を適切にコントロールするための治療ギャップの存在です。現在、多くの患者が効果的な治療法にアクセスできていないため、革新的な治療法の需要が浮き彫りになり、製薬企業は研究開発（R&D）への投資を促しています。これは、患者の治療を向上させるだけでなく、大きな市場機会をも意味します。

世界のヘルスケア産業の急速な拡大も、急性群発発作市場を刺激する大きな動向です。ヘルスケアのインフラが成長するにつれて、医療へのアクセスも増加し、効果的な発作管理に対する需要も高まっています。同市場は、世界のヘルスケア産業の拡大から利益を得ようとしています。

抗てんかん薬（AED）は、確立された有効性、多様な選択肢、製剤の改良と副作用の軽減につながる継続的な研究開発努力により、急性群発発作市場で大きな成長を遂げています。AEDは、発作管理に適した選択肢となっています。

経口投与は、その利便性、患者のコンプライアンス、経口剤形状のAEDが広く入手可能であることから、急性群発発作市場において重要性を増しています。この非侵襲的な方法は長期的な発作管理を簡素化し、市場の成長に寄与しています。

病院は急性群発発作市場における主要な流通チャネルとして台頭してきており、急性発作管理の主要な拠点となっています。一方、在宅ケアは、患者中心のケア、携帯医療機器、遠隔医療の動向により、効率的で利便性の高い在宅ケアとして成長しています。

当レポートでは、世界の急性群発発作市場について調査し、市場の概要とともに、薬剤タイプ別、投与経路別、流通チャネル別、最終用途別、地域別動向、および市場に参入する企業の競合動向などを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の定義とセグメンテーション
  • 市場力学
  • バリューチェーン分析
  • ポーターのファイブフォース分析
  • COVID-19の影響分析
  • ウクライナとロシアの紛争の影響
  • 経済概要
  • PESTLE分析

第3章 世界の急性群発発作市場の見通し、2018年～2030年

  • 世界の急性群発発作市場の見通し、薬剤タイプ別、金額（10億米ドル）、2018年～2030年
  • 世界の急性群発発作市場の見通し、投与経路別、金額（10億米ドル）、2018年～2030年
  • 世界の急性群発発作市場の見通し、流通チャネル別、金額（10億米ドル）、2018年～2030年
  • 世界の急性群発発作市場の見通し、最終用途別、金額（10億米ドル）、2018年～2030年
  • 世界の急性群発発作市場の見通し、地域別、金額（10億米ドル）、2018年～2030年

第4章 北米の急性群発発作市場の見通し、2018年～2030年

第5章 欧州の急性群発発作市場の見通し、2018年～2030年

第6章 アジア太平洋の急性群発発作市場の見通し、2018年～2030年

第7章 ラテンアメリカの急性群発発作市場の見通し、2018年～2030年

第8章 中東・アフリカの急性群発発作市場の見通し、2018年～2030年

第9章 競合情勢

  • 流通チャネルと用途のヒートマップ
  • メーカーと用途のヒートマップ
  • 企業の市場シェア分析、2022年
  • 競争力ダッシュボード
  • 企業プロファイル
    • Pfizer
    • Novartis
    • GlaxoSmithKline
    • Eisai Co. Ltd.
    • UCB Pharmaceuticals
    • Lundbeck
    • UCB
    • Acquestive Therapeutics
    • Marinus Pharmaceuticals
    • Takeda Pharmaceuticals
    • SK Biopharmaceuticals
    • Supernus Pharmaceuticals
    • Neurelis Inc.
    • Sage Therapeutics
    • NeuroPace

第10章 付録

  • 調査手法
  • レポートの前提条件
  • 頭字語と略語
目次

Global Acute Repetitive Seizures Market Projected to Reach $13.5 Billion by 2030: Rapid Growth and Key Trends Shape the Industry.

The global acute repetitive seizures market is on a trajectory of remarkable growth, with projections indicating a market size of $13.5 billion by the end of 2030, driven by a robust CAGR of 30% between 2023 and 2030. Fairfield Market Research's latest report provides a comprehensive overview of this burgeoning market, highlighting key trends, growth determinants, and the competitive landscape.

Key Trends Driving Growth in the Acute Repetitive Seizures Market

Presence of a Treatment Gap and R&D Initiatives: One of the primary trends propelling the acute repetitive seizures market is the presence of a treatment gap in achieving adequate seizure control. Many patients currently lack access to effective therapies, highlighting the demand for innovative treatments and prompting pharmaceutical companies to invest in research and development (R&D). This not only enhances patient care but also represents a significant market opportunity.

Rapidly Expanding Global Healthcare Industry: The global healthcare industry's rapid expansion is another major trend fueling the acute repetitive seizures market. As healthcare infrastructure grows, so does access to care and the demand for effective seizure management. The market is set to profit from the worldwide healthcare industry's expansion.

Dominance of Antiepileptic Drugs (AEDs): Antiepileptic drugs (AEDs) are experiencing significant growth in the acute repetitive seizures market due to their well-established efficacy, diverse options, and continuous R&D efforts leading to improved formulations and reduced side effects. AEDs have become the preferred choice for seizure management.

Growing Importance of the Oral Route: The oral route of administration is gaining prominence in the acute repetitive seizures market due to its convenience, patient compliance, and the wide availability of AEDs in oral forms. This non-invasive method simplifies long-term seizure management, contributing to its growth.

Hospitals and Home Care Settings: Hospitals are emerging as a key distribution channel in the acute repetitive seizures market, serving as primary centers for acute seizure management. In contrast, home care settings are growing due to the trend toward patient-centric care, portable medical devices, and telemedicine, making home care efficient and convenient.

Regional Insights

North America Leads the Way: North America has captured the largest market share in the acute repetitive seizures market. This dominance is attributed to its advanced healthcare infrastructure, high disease prevalence, strong R&D investments, favorable regulations, and a robust pharmaceutical industry. North America plays a dominant role in seizure management and treatment.

Asia Pacific Shows Exceptional Growth: The Asia Pacific region is poised to witness the highest CAGR in the acute repetitive seizures market. Factors such as a large patient population, increasing healthcare infrastructure, rising awareness, and expanding access to care are driving remarkable growth in this rapidly evolving market.

Competitive Landscape

The global acute repetitive seizures market is characterized by consolidation, with a select group of major players dominating the industry. These key players, including Pfizer, Novartis, GlaxoSmithKline, Eisai Co., Ltd, UCB Pharmaceuticals, Lundbeck, UCB, Aquestive Therapeutics, Marinus Pharmaceuticals, Takeda Pharmaceuticals, SK Biopharmaceuticals, Supernus Pharmaceuticals, Neurelis, Inc., Sage Therapeutics, NeuroPace, Inc and others, are actively introducing new products and expanding their distribution channels to bolster their international presence.

Table of Contents

1. Executive Summary

  • 1.1. Global Acute Repetitive Seizures Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2022
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. Covid-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Acute Repetitive Seizures Market Outlook, 2018 - 2030

  • 3.1. Global Acute Repetitive Seizures Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2030
    • 3.1.1. Key Highlights
      • 3.1.1.1. Antiepileptic Drugs (AEDs)
      • 3.1.1.2. Benzodiazepines
      • 3.1.1.3. Barbiturates
      • 3.1.1.4. Others
  • 3.2. Global Acute Repetitive Seizures Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2030
    • 3.2.1. Key Highlights
      • 3.2.1.1. Oral
      • 3.2.1.2. Intravenous
      • 3.2.1.3. Intranasal
  • 3.3. Global Acute Repetitive Seizures Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 3.3.1. Key Highlights
      • 3.3.1.1. Hospitals
      • 3.3.1.2. Specialty Clinics
      • 3.3.1.3. Retail Pharmacies
      • 3.3.1.4. Online Pharmacies
  • 3.4. Global Acute Repetitive Seizures Market Outlook, by End Use, Value (US$ Bn), 2018 - 2030
    • 3.4.1. Key Highlights Snacks
      • 3.4.1.1. Hospitals
      • 3.4.1.2. Clinics
      • 3.4.1.3. Home Care Settings
  • 3.5. Global Acute Repetitive Seizures Market Outlook, by Region, Value (US$ Bn), 2018 - 2030
    • 3.5.1. Key Highlights
      • 3.5.1.1. North America
      • 3.5.1.2. Europe
      • 3.5.1.3. Asia Pacific
      • 3.5.1.4. Latin America
      • 3.5.1.5. Middle East & Africa

4. North America Acute Repetitive Seizures Market Outlook, 2018 - 2030

  • 4.1. North America Acute Repetitive Seizures Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2030
    • 4.1.1. Key Highlights
      • 4.1.1.1. Antiepileptic Drugs (AEDs)
      • 4.1.1.2. Benzodiazepines
      • 4.1.1.3. Barbiturates
      • 4.1.1.4. Others
  • 4.2. North America Acute Repetitive Seizures Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2030
    • 4.2.1. Key Highlights
      • 4.2.1.1. Oral
      • 4.2.1.2. Intravenous
      • 4.2.1.3. Intranasal
  • 4.3. North America Acute Repetitive Seizures Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 4.3.1. Key Highlights
      • 4.3.1.1. Hospitals
      • 4.3.1.2. Specialty Clinics
      • 4.3.1.3. Retail Pharmacies
      • 4.3.1.4. Online Pharmacies
  • 4.4. North America Acute Repetitive Seizures Market Outlook, by End Use, Value (US$ Bn), 2018 - 2030
    • 4.4.1. Key Highlights
      • 4.4.1.1. Hospitals
      • 4.4.1.2. Clinics
      • 4.4.1.3. Home Care Settings
    • 4.4.2. BPS Analysis/Market Attractiveness Analysis
  • 4.5. North America Acute Repetitive Seizures Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 4.5.1. Key Highlights
      • 4.5.1.1. U.S. Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 4.5.1.2. U.S. Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 4.5.1.3. U.S. Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 4.5.1.4. U.S. Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
      • 4.5.1.5. Canada Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 4.5.1.6. Canada Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 4.5.1.7. Canada Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 4.5.1.8. Canada Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
    • 4.5.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Acute Repetitive Seizures Market Outlook, 2018 - 2030

  • 5.1. Europe Acute Repetitive Seizures Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2030
    • 5.1.1. Key Highlights
      • 5.1.1.1. Antiepileptic Drugs (AEDs)
      • 5.1.1.2. Benzodiazepines
      • 5.1.1.3. Barbiturates
      • 5.1.1.4. Others
  • 5.2. Europe Acute Repetitive Seizures Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2030
    • 5.2.1. Key Highlights
      • 5.2.1.1. Oral
      • 5.2.1.2. Intravenous
      • 5.2.1.3. Intranasal
  • 5.3. Europe Acute Repetitive Seizures Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 5.3.1. Key Highlights
      • 5.3.1.1. Hospitals
      • 5.3.1.2. Specialty Clinics
      • 5.3.1.3. Retail Pharmacies
      • 5.3.1.4. Online Pharmacies
  • 5.4. Europe Acute Repetitive Seizures Market Outlook, by End Use, Value (US$ Bn), 2018 - 2030
    • 5.4.1. Key Highlights
      • 5.4.1.1. Hospitals
      • 5.4.1.2. Clinics
      • 5.4.1.3. Home Care Settings
    • 5.4.2. BPS Analysis/Market Attractiveness Analysis
  • 5.5. Europe Acute Repetitive Seizures Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 5.5.1. Key Highlights
      • 5.5.1.1. Germany Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 5.5.1.2. Germany Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 5.5.1.3. Germany Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 5.5.1.4. Germany Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
      • 5.5.1.5. U.K. Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 5.5.1.6. U.K. Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 5.5.1.7. U.K. Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 5.5.1.8. U.K. Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
      • 5.5.1.9. France Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 5.5.1.10. France Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 5.5.1.11. France Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 5.5.1.12. France Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
      • 5.5.1.13. Italy Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 5.5.1.14. Italy Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 5.5.1.15. Italy Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 5.5.1.16. Italy Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
      • 5.5.1.17. Spain Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 5.5.1.18. Spain Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 5.5.1.19. Spain Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 5.5.1.20. Spain Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
      • 5.5.1.21. Rest of Europe Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 5.5.1.22. Rest of Europe Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 5.5.1.23. Rest of Europe Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 5.5.1.24. Rest of Europe Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
    • 5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Acute Repetitive Seizures Market Outlook, 2018 - 2030

  • 6.1. Asia Pacific Acute Repetitive Seizures Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2030
    • 6.1.1. Key Highlights
      • 6.1.1.1. Antiepileptic Drugs (AEDs)
      • 6.1.1.2. Benzodiazepines
      • 6.1.1.3. Barbiturates
      • 6.1.1.4. Others
  • 6.2. Asia Pacific Acute Repetitive Seizures Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2030
    • 6.2.1. Key Highlights
      • 6.2.1.1. Oral
      • 6.2.1.2. Intravenous
      • 6.2.1.3. Intranasal
  • 6.3. Asia Pacific Acute Repetitive Seizures Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 6.3.1. Key Highlights
      • 6.3.1.1. Hospitals
      • 6.3.1.2. Specialty Clinics
      • 6.3.1.3. Retail Pharmacies
      • 6.3.1.4. Online Pharmacies
  • 6.4. Asia Pacific Acute Repetitive Seizures Market Outlook, by End Use, Value (US$ Bn), 2018 - 2030
    • 6.4.1. Key Highlights
      • 6.4.1.1. Hospitals
      • 6.4.1.2. Clinics
      • 6.4.1.3. Home Care Settings
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis
  • 6.5. Asia Pacific Acute Repetitive Seizures Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 6.5.1. Key Highlights
      • 6.5.1.1. China Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 6.5.1.2. China Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 6.5.1.3. China Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 6.5.1.4. China Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
      • 6.5.1.5. Japan Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 6.5.1.6. Japan Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 6.5.1.7. Japan Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 6.5.1.8. Japan Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
      • 6.5.1.9. India Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 6.5.1.10. India Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 6.5.1.11. India Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 6.5.1.12. India Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
      • 6.5.1.13. Southeast Asia Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 6.5.1.14. Southeast Asia Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 6.5.1.15. Southeast Asia Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 6.5.1.16. Southeast Asia Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
      • 6.5.1.17. Rest of Asia Pacific Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 6.5.1.18. Rest of Asia Pacific Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 6.5.1.19. Rest of Asia Pacific Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 6.5.1.20. Rest of Asia Pacific Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
    • 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Acute Repetitive Seizures Market Outlook, 2018 - 2030

  • 7.1. Latin America Acute Repetitive Seizures Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2030
    • 7.1.1. Key Highlights
      • 7.1.1.1. Antiepileptic Drugs (AEDs)
      • 7.1.1.2. Benzodiazepines
      • 7.1.1.3. Barbiturates
      • 7.1.1.4. Others
  • 7.2. Latin America Acute Repetitive Seizures Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2030
    • 7.2.1. Key Highlights
      • 7.2.1.1. Oral
      • 7.2.1.2. Intravenous
      • 7.2.1.3. Intranasal
  • 7.3. Latin America Acute Repetitive Seizures Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 7.3.1. Key Highlights
      • 7.3.1.1. Hospitals
      • 7.3.1.2. Specialty Clinics
      • 7.3.1.3. Retail Pharmacies
      • 7.3.1.4. Online Pharmacies
  • 7.4. Latin America Acute Repetitive Seizures Market Outlook, by End Use, Value (US$ Bn), 2018 - 2030
    • 7.4.1. Key Highlights
      • 7.4.1.1. Hospitals
      • 7.4.1.2. Clinics
      • 7.4.1.3. Home Care Settings
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis
  • 7.5. Latin America Acute Repetitive Seizures Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 7.5.1. Key Highlights
      • 7.5.1.1. Brazil Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 7.5.1.2. Brazil Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 7.5.1.3. Brazil Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 7.5.1.4. Brazil Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
      • 7.5.1.5. Mexico Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 7.5.1.6. Mexico Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 7.5.1.7. Mexico Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 7.5.1.8. Mexico Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
      • 7.5.1.9. Rest of Latin America Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 7.5.1.10. Rest of Latin America Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 7.5.1.11. Rest of Latin America Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 7.5.1.12. Rest of Latin America Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
    • 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Acute Repetitive Seizures Market Outlook, 2018 - 2030

  • 8.1. Middle East & Africa Acute Repetitive Seizures Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2030
    • 8.1.1. Key Highlights
      • 8.1.1.1. Antiepileptic Drugs (AEDs)
      • 8.1.1.2. Benzodiazepines
      • 8.1.1.3. Barbiturates
      • 8.1.1.4. Others
  • 8.2. Middle East & Africa Acute Repetitive Seizures Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2030
    • 8.2.1. Key Highlights
      • 8.2.1.1. Oral
      • 8.2.1.2. Intravenous
      • 8.2.1.3. Intranasal
  • 8.3. Middle East & Africa Acute Repetitive Seizures Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 8.3.1. Key Highlights
      • 8.3.1.1. Hospitals
      • 8.3.1.2. Specialty Clinics
      • 8.3.1.3. Retail Pharmacies
      • 8.3.1.4. Online Pharmacies
  • 8.4. Middle East & Africa Acute Repetitive Seizures Market Outlook, by End Use, Value (US$ Bn), 2018 - 2030
    • 8.4.1. Key Highlights
      • 8.4.1.1. Hospitals
      • 8.4.1.2. Clinics
      • 8.4.1.3. Home Care Settings
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis
  • 8.5. Middle East & Africa Acute Repetitive Seizures Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 8.5.1. Key Highlights
      • 8.5.1.1. GCC Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 8.5.1.2. GCC Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 8.5.1.3. GCC Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 8.5.1.4. GCC Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
      • 8.5.1.5. South Africa Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 8.5.1.6. South Africa Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 8.5.1.7. South Africa Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 8.5.1.8. South Africa Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
      • 8.5.1.9. Rest of Middle East & Africa Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 8.5.1.10. Rest of Middle East & Africa Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 8.5.1.11. Rest of Middle East & Africa Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 8.5.1.12. Rest of Middle East & Africa Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
    • 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Distribution Channel vs Application Heatmap
  • 9.2. Manufacturer vs Application Heatmap
  • 9.3. Company Market Share Analysis, 2022
  • 9.4. Competitive Dashboard
  • 9.5. Company Profiles
    • 9.5.1. Pfizer
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Product Portfolio
      • 9.5.1.3. Financial Overview
      • 9.5.1.4. Business Strategies and Development
    • 9.5.2. Novartis
      • 9.5.2.1. Company Overview
      • 9.5.2.2. Product Portfolio
      • 9.5.2.3. Financial Overview
      • 9.5.2.4. Business Strategies and Development
    • 9.5.3. GlaxoSmithKline
      • 9.5.3.1. Company Overview
      • 9.5.3.2. Product Portfolio
      • 9.5.3.3. Financial Overview
      • 9.5.3.4. Business Strategies and Development
    • 9.5.4. Eisai Co. Ltd.
      • 9.5.4.1. Company Overview
      • 9.5.4.2. Product Portfolio
      • 9.5.4.3. Financial Overview
      • 9.5.4.4. Business Strategies and Development
    • 9.5.5. UCB Pharmaceuticals
      • 9.5.5.1. Company Overview
      • 9.5.5.2. Product Portfolio
      • 9.5.5.3. Financial Overview
      • 9.5.5.4. Business Strategies and Development
    • 9.5.6. Lundbeck
      • 9.5.6.1. Company Overview
      • 9.5.6.2. Product Portfolio
      • 9.5.6.3. Financial Overview
      • 9.5.6.4. Business Strategies and Development
    • 9.5.7. UCB
      • 9.5.7.1. Company Overview
      • 9.5.7.2. Product Portfolio
      • 9.5.7.3. Financial Overview
      • 9.5.7.4. Business Strategies and Development
    • 9.5.8. Acquestive Therapeutics
      • 9.5.8.1. Company Overview
      • 9.5.8.2. Product Portfolio
      • 9.5.8.3. Business Strategies and Development
    • 9.5.9. Marinus Pharmaceuticals
      • 9.5.9.1. Company Overview
      • 9.5.9.2. Product Portfolio
      • 9.5.9.3. Financial Overview
      • 9.5.9.4. Business Strategies and Development
    • 9.5.10. Takeda Pharmaceuticals
      • 9.5.10.1. Company Overview
      • 9.5.10.2. Product Portfolio
      • 9.5.10.3. Financial Overview
      • 9.5.10.4. Business Strategies and Development
    • 9.5.11. SK Biopharmaceuticals
      • 9.5.11.1. Company Overview
      • 9.5.11.2. Product Portfolio
      • 9.5.11.3. Financial Overview
      • 9.5.11.4. Business Strategies and Development
    • 9.5.12. Supernus Pharmaceuticals
      • 9.5.12.1. Company Overview
      • 9.5.12.2. Product Portfolio
      • 9.5.12.3. Financial Overview
      • 9.5.12.4. Business Strategies and Development
    • 9.5.13. Neurelis Inc.
      • 9.5.13.1. Company Overview
      • 9.5.13.2. Product Portfolio
      • 9.5.13.3. Financial Overview
      • 9.5.13.4. Business Strategies and Development
    • 9.5.14. Sage Therapeutics
      • 9.5.14.1. Company Overview
      • 9.5.14.2. Product Portfolio
      • 9.5.14.3. Financial Overview
      • 9.5.14.4. Business Strategies and Development
    • 9.5.15. NeuroPace
      • 9.5.15.1. Company Overview
      • 9.5.15.2. Product Portfolio
      • 9.5.15.3. Financial Overview
      • 9.5.15.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations